SCHEMBL13836337

SCHEMBL13836337

COc1ccc(C(NC(=O)C(C)C)c2cc([N+](=O)[O-])c3cccnc3c2O)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.81
KMT2A Q03164 10/20 0.81
MAPT P10636 10/20 0.81
HTT P42858 10/20 0.81
MEN1 O00255 9/20 0.81
L3MBTL1 Q9Y468 9/20 0.81
LMNA P02545 9/20 0.81
SMN1; SMN2 Q16637 9/20 0.81
TDP1 Q9NUW8 8/20 0.81
CCR6 P51684 2/20 0.81
RECQL P46063 1/20 0.81
ALOX12 P18054 7/20 0.80
POLB P06746 1/20 0.80
BLM P54132 1/20 0.68
NPC1 O15118 2/20 0.67
RAB9A P51151 2/20 0.67
ALDH1A1 P00352 1/20 0.67
PKM P14618 1/20 0.67
ADAMTS5 Q9UNA0 6/20 0.63
TP53 P04637 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30868633 0.91 KMT2A (0.80) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL31533580 0.91 KDM4E (0.67) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL2153199 0.90 KDM4E (0.87) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL2153850 0.89 MAPT (1.00) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL13836483 0.89 HTT (0.75) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL13310332 0.89 KDM4E (0.81) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL2153325 0.89 MEN1 (0.84) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL31533567 0.88 KDM4E (0.64) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL31533558 0.88 LMNA (0.69) KDM4EKMT2AMAPTHTTMEN1
SCHEMBL31672843 0.87 KDM4E (0.63) KDM4EKMT2AMAPTHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103444-A1 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF UNIV OSAKA (JP) 2026-04-16 US disclosed
EP-4599832-A1 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF OSAKA UNIVERSITY (JP) 2025-08-13 EP disclosed
WO-2024075815-A1 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF 国立大学法人大阪大学 2024-04-11 WO disclosed
US-20120295890-A1 GLYCOSAMINOGLYCAN INHIBITORS Zacharon Pharmaceutical, Inc. (US) 2012-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295890-A1 GLYCOSAMINOGLYCAN INHIBITORS CSGALNACT1, FUT5, ST3GAL3 KDM4E 4113/4885KMT2A 4294/4885MAPT 4328/4885
US-20260103444-A1 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF MYLK2, MYLK, ATP2A1 KDM4E 2263/4885KMT2A 1971/4885MAPT 4694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.